Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.

Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.

A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain

Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.

Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.

Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.